SKF-38393 is a potent, selective D1/D5 receptor partial agonist with Ki of 1 and 0.5 nM, respectively.

SK609 (SK-609, ES609) is a potent, selective agonist of dopamine D3 receptor with a bias towards the G-protein-dependent pathway rather than recruiting β-arrestin-2 and an EC50 value of 113.9 nM for activation of ERK1/2 phosphorylation.

SK 216 is a potent, selective inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 44 uM.

SJ830599 is a modest selective BRD2-BD2 inhibitor with IC50 of 0.61 uM, 3.3-fold selectivity over BRD2-BD1.

SJ-733 (SJ000557733.

Sitagliptin phosphate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.

SIRT2 inhibitor AEM2 (AEM2) is a selective SIRT2 inhibitor with IC50 of 3.8 uM, shows only weak effects on other sirtuins such as SIRT1, SIRT3, and yeast Sir2.

SirT1 enhancer A03 is a specific, orally bioavailable, brain penetrant apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic SirT2 in vitro in ApoE4-

Siomycin A (NSC 285116) is an antibiotic thiazole inhibitor of the oncogenic transcription factor FOXM1, down-regulates the transcriptional activity as well as the protein and mRNA abundance of FoxM1.

Sinefungin (A 9145.

Sincalide (CCK-8) is a 8-amino acid C-terminal fragment of cholecystokinin.

Simotinib (SIM-6802) is a novel potent EGFR inhibitor for treatment of NSCLC..

Simmiparib is a novel potent, orally active PARP1/2 inhibitor with IC50 of 1.75/0.22 nM, inhibits PARP1 >90-fold more potently than the other PARPs (PARP3, TNKS1, TNKS2).

Silymarin (Silybin B)

Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.

Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.

Sildenafil Mesylate is a mesylate form of Sildenafil, an inhibitor of Phosphodiesterase 5.

Sigma1-IN-4 is a novel small molecule sigma-1 receptor inhibitor with Ki of 38 nM.

SIG1459 (SIG-1459) is a novel anti-acne isoprenylcysteine (IPC) small molecule that shows direct antibacterial activity and inhibits TLR2 inflammatory signaling.

SIG-1191 (SIG1191) is a soprenylcysteine (IPC) small molecule with anti-inflammatory activity, inhibits UVB-induced inflammation blocking pro-inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production.

sibutramine hydrochloride

SHR3824 is a potent, selective SGLT2 inhibitor with IC50 of 2.38 nM, >1000-fold selectivity over SGLT1.

SHP836 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 12 uM (SHP2 1-525), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM).downregulates DUSP6 mRNA, a downstream MAPK pathway marker, in KYSE-520 cancer cells.

SHP389 (SHP-389, SHP 389) is a novel potent, selective, allosteric SHP2 inhibitor with IC50 of 36 nM, shows with impressive hERG selectivity (IC50>30 uM).

SHP2-IN-2 is a selective, allosteric inhibitor of protein tyrosine phosphatase SHP2, preferentially inhibits SHP2 F285S over the PTP domain and allosteric site mutant.

SHP244 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 60 uM (SHP2 1-525), equipotent on the double mutant (SHP2T253M/Q257L IC50=68 uM), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM)..

SHP2 inhibitor LY6 (LY6) is a small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2, inhibits SHP2 with IC50 of 9.8 uM, 7-fold selectivity over SHP1.

SHP2 inhibitor 9 is a potent, selective inhibitor of SHP2 with IC50 of 48 nM, inhibits p-ERK in KYSE520 cells with IC50 of 28 nM.

SHP2 inhibitor 8 is a potent, selective inhibitor of SHP2 with IC50 of 5 nM, inhibits p-ERK in KYSE520 cells with IC50 of 5 nM.

SHP2 inhibitor 14 is a novel potent, selective, allosteric, orally acitve SHP2 inhibitor with IC50 of 28 nM.